For many investors, the main point of stock picking is to generate higher returns than the overall market. But the risk of stock picking is that you will likely buy under-performing companies. Unfortunately, that's been the case for longer term Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399) shareholders, since the share price is down 25% in the last three years, falling well short of the market return of around 23%. Furthermore, it's down 11% in about a quarter. That's not much fun for holders.
So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.
View our latest analysis for Shenzhen Hepalink Pharmaceutical Group
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.
During the three years that the share price fell, Shenzhen Hepalink Pharmaceutical Group's earnings per share (EPS) dropped by 23% each year. This fall in the EPS is worse than the 9% compound annual share price fall. This suggests that the market retains some optimism around long term earnings stability, despite past EPS declines. This positive sentiment is also reflected in the generous P/E ratio of 46.72.
You can see below how EPS has changed over time (discover the exact values by clicking on the image).
![earnings-per-share-growth](https://usnewsfile.futunn.com/pic/0-17786596-0-57ccab0f6eba38479e07ebe41238e3d4.png/big)
SZSE:002399 Earnings Per Share Growth December 15th 2022
Dive deeper into Shenzhen Hepalink Pharmaceutical Group's key metrics by checking this interactive graph of Shenzhen Hepalink Pharmaceutical Group's earnings, revenue and cash flow.
A Different Perspective
While it's certainly disappointing to see that Shenzhen Hepalink Pharmaceutical Group shares lost 15% throughout the year, that wasn't as bad as the market loss of 17%. Unfortunately, last year's performance may indicate unresolved challenges, given that it's worse than the annualised loss of 3% over the last half decade. While some investors do well specializing in buying companies that are struggling (but nonetheless undervalued), don't forget that Buffett said that 'turnarounds seldom turn'. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 2 warning signs we've spotted with Shenzhen Hepalink Pharmaceutical Group .
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on CN exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对于许多投资者来说,选股的主要着眼点是产生高于整体市场的回报。但选股的风险是,你可能会买入表现不佳的公司。不幸的是,从长远来看,情况就是这样深圳市海普力克药业集团有限公司。(SZSE:002399)股东,因为过去三年股价下跌了25%,远远低于约23%的市场回报率。此外,它在大约四分之一的时间里下跌了11%。对于持有者来说,这并不是什么乐趣。
因此,让我们来看看该公司的长期业绩是否与基础业务的进展一致。
查看我们对深圳海普林药业集团的最新分析
虽然有效市场假说继续被一些人传授,但事实证明,市场是过度反应的动态系统,投资者并不总是理性的。评估围绕一家公司的情绪变化的一个有缺陷但合理的方法是将每股收益(EPS)与股价进行比较。
在股价下跌的三年里,深圳海普林药业集团的每股收益(EPS)每年下降23%。每股收益的这一跌幅比9%的复合年度股价跌幅还要糟糕。这表明,尽管过去每股收益有所下降,但市场仍对长期收益稳定保持了一定的乐观情绪。这种积极情绪也反映在46.72的慷慨市盈率上。
您可以在下面看到EPS是如何随着时间的推移而变化的(通过单击图像来了解确切的值)。
![earnings-per-share-growth](https://usnewsfile.futunn.com/pic/0-17786596-0-57ccab0f6eba38479e07ebe41238e3d4.png/big)
上交所:2022年12月15日每股收益增长002399
通过查看深圳海普林药业集团的收益、收入和现金流的互动图表,更深入地了解深圳海普林克药业集团的关键指标。
不同的视角
尽管看到深圳海普瑞药业集团股价全年下跌15%肯定令人失望,但这并没有股市下跌17%那么糟糕。不幸的是,去年的表现可能预示着尚未解决的挑战,因为它比过去五年3%的年化损失更糟糕。虽然一些投资者擅长买入那些陷入困境(但估值仍然被低估)的公司,但不要忘记巴菲特曾说过,扭亏为盈的情况很少出现转机。虽然值得考虑市场状况对股价可能产生的不同影响,但还有其他更重要的因素。为此,您应该意识到2个警告标志我们已经发现了深圳海普林药业集团。
如果你喜欢和管理层一起买股票,那么你可能会喜欢这本书免费公司名单。(提示:内部人士一直在买入这些股票)。
请注意,本文引用的市场回报反映了目前在CN交易所交易的股票的市场加权平均回报。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。